Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 2/2012

01-08-2012 | Gynecologic Oncology

The potential prognostic value of cathepsin D protein in serous ovarian cancer

Authors: Yun Chai, Weiwei Wu, Caiyun Zhou, Jianhong Zhou

Published in: Archives of Gynecology and Obstetrics | Issue 2/2012

Login to get access

Abstract

Objectives

Overexpression of a ubiquitous lysosomal aspartyl protease cathepsin D (cath-D) is involved in the progression of certain cancer types. This study investigated the prognostic value of the cath-D expression and its association with other known clinicopathological parameters in serous ovarian carcinoma.

Materials and methods

Cath-D was detected by immunohistochemistry in 49 serous ovarian carcinomas and compared to 50 benign serous ovarian tumors. The results were correlated with clinicopathological characteristics and survival outcomes.

Results

In both cath-D positive benign and malignant serous ovarian tumors, a specific granular cytoplasmic staining was observed in both epithelial and stromal cells. Cath-D expression levels were higher in serous ovarian carcinomas than in benign tumors (P < 0.01). Cath-D expression in tumor epithelial cells correlated with mesenchymal cell expression (P < 0.001). The cath-D expression levels of tumor epithelial cells correlated with residual tumor size (P = 0.027) and was not related to other factors (P > 0.05). Patients with higher cath-D expression in epithelial cells had longer disease-free survival time (DFST; P = 0.025) and overall survival time (OST; P = 0.030). Through the Cox regression test, we found that the response to treatment (P < 0.001), pathological stage (P < 0.001), and peritoneal cytology results (P = 0.018) were independent effect factors for DFST. The expression level of cath-D in epithelial cells (P = 0.025), response to treatment (P < 0.001), pathological stage (P = 0.001), and peritoneal cytology results (P = 0.002) were independent effect factors for OST.

Conclusion

This showed that cath-D was an indicator of malignancy in serous ovarian carcinoma. It was expressed more highly in serous ovarian carcinoma than benign serous ovarian tumor. Additionally, our results suggested that high expression of cath-D in tumor epithelial cells was a favorable survival prognostic factor for serous ovarian carcinoma.
Literature
1.
2.
go back to reference Nomura T, Katunuma N (2005) Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 52(1–2):1–9PubMedCrossRef Nomura T, Katunuma N (2005) Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 52(1–2):1–9PubMedCrossRef
3.
go back to reference Clinton GM, Hua W (1997) Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25(1):1–9PubMedCrossRef Clinton GM, Hua W (1997) Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25(1):1–9PubMedCrossRef
4.
go back to reference Berchem G, Glonda M, Gleizes M et al (2002) Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21(38):5951–5955PubMedCrossRef Berchem G, Glonda M, Gleizes M et al (2002) Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21(38):5951–5955PubMedCrossRef
5.
go back to reference Leto G, Tumminello FM, Crescimanno M et al (2004) Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis 21(2):91–106PubMedCrossRef Leto G, Tumminello FM, Crescimanno M et al (2004) Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis 21(2):91–106PubMedCrossRef
6.
go back to reference Rochefort H (1992) Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A(11):1780–1783PubMedCrossRef Rochefort H (1992) Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A(11):1780–1783PubMedCrossRef
7.
go back to reference Foekens JA, Look MP, Bolt-de Vries J et al (1999) Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79(2):300–307PubMedCrossRef Foekens JA, Look MP, Bolt-de Vries J et al (1999) Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79(2):300–307PubMedCrossRef
8.
go back to reference Henzen-Logmans SC, Fieret EJ, Berns EM et al (1994) Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal growth factor receptor and cathepsin D. Int J Cancer 57(4):468–472PubMedCrossRef Henzen-Logmans SC, Fieret EJ, Berns EM et al (1994) Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal growth factor receptor and cathepsin D. Int J Cancer 57(4):468–472PubMedCrossRef
9.
go back to reference Baekelandt M, Holm R, Trope CG et al (1999) The significance of metastasis-related facts cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol 10(11):1335–1341PubMedCrossRef Baekelandt M, Holm R, Trope CG et al (1999) The significance of metastasis-related facts cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol 10(11):1335–1341PubMedCrossRef
10.
go back to reference Scambia G, Panici PB, Ferrandina G et al (1994) Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 30A:935–940PubMedCrossRef Scambia G, Panici PB, Ferrandina G et al (1994) Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 30A:935–940PubMedCrossRef
11.
go back to reference Ferrandina G, Scambia G, Fagotti A et al (1998) Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer 78(12):1645–1652PubMedCrossRef Ferrandina G, Scambia G, Fagotti A et al (1998) Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer 78(12):1645–1652PubMedCrossRef
12.
go back to reference Athanassiadou P, Sakellariou V, Petrakakou E et al (1998) Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors. Pathol Oncol 4(2):103–107CrossRef Athanassiadou P, Sakellariou V, Petrakakou E et al (1998) Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors. Pathol Oncol 4(2):103–107CrossRef
13.
go back to reference Losch A, Schindl M, Kohlberger P et al (2004) Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 92(2):545–552PubMedCrossRef Losch A, Schindl M, Kohlberger P et al (2004) Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 92(2):545–552PubMedCrossRef
14.
go back to reference Nisolle M, Casanas RF, Donnez J (1997) Immunohistochemical analysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertil Steril 68(5):912–919PubMedCrossRef Nisolle M, Casanas RF, Donnez J (1997) Immunohistochemical analysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertil Steril 68(5):912–919PubMedCrossRef
15.
go back to reference Dvalishvili I, Charkviani L, Charkviani T et al (2005) Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma. Georgian Med News 126:27–31PubMed Dvalishvili I, Charkviani L, Charkviani T et al (2005) Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma. Georgian Med News 126:27–31PubMed
16.
go back to reference Rodríguez J, Vázquez J, Corte MD et al (2005) Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 20(2):103–111PubMed Rodríguez J, Vázquez J, Corte MD et al (2005) Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 20(2):103–111PubMed
17.
go back to reference Abbott DE, Margaryan NV, Jeruss JS et al (2010) Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 9(1):23–30PubMedCrossRef Abbott DE, Margaryan NV, Jeruss JS et al (2010) Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 9(1):23–30PubMedCrossRef
18.
go back to reference Maygarden SJ, Novotny DB, Moul JW et al (1994) Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol 7(9):930–9366PubMed Maygarden SJ, Novotny DB, Moul JW et al (1994) Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol 7(9):930–9366PubMed
19.
go back to reference Holm R, Tanum G (1996) Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study. Virchows Arch 428(2):85–89PubMedCrossRef Holm R, Tanum G (1996) Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study. Virchows Arch 428(2):85–89PubMedCrossRef
20.
go back to reference Axel SM, Joerg H, Perikles S et al (2005) Translational research: from lab to clinic: cathepsin D expression in renal cell cancer clinical implications. Eur Urol 48:519–526CrossRef Axel SM, Joerg H, Perikles S et al (2005) Translational research: from lab to clinic: cathepsin D expression in renal cell cancer clinical implications. Eur Urol 48:519–526CrossRef
Metadata
Title
The potential prognostic value of cathepsin D protein in serous ovarian cancer
Authors
Yun Chai
Weiwei Wu
Caiyun Zhou
Jianhong Zhou
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 2/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2318-2

Other articles of this Issue 2/2012

Archives of Gynecology and Obstetrics 2/2012 Go to the issue